← Back to screener

Kura Oncology, Inc. KURA

Rank #2188 · Nasdaq · $0.9B market cap
Audited by Ernst & Young LLP, no going-concern flag in the latest filing.
Score
30.0
P/E
-6.0
P/B
2.17
ROE
-36.3%
Op. Margin
–%
Debt Ratio
82%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆
Weak

P/E -6.0x, P/B 2.17x. Ranks in the top 64% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -36.3%. Ranks in the top 86% of the universe.

Safety ★★★☆☆
Good

Debt ratio 82%. Ranks in the top 34% of the universe.

Growth ★☆☆☆☆
Poor

Revenue decline of 100.0% year over year. Ranks in the top 100% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2011–$-0.0B$-0.0B$0.0B––
2012–$-0.0B$-0.0B$0.0B––
2013–$-0.0B$-0.0B$0.0B–296
2014–$-0.0B$-0.0B$0.0B–380
2015––$-0.0B$0.0B––
2016––$-0.0B$-0.0B–-150
2017––$-0.0B$0.1B–16
2018––$-0.0B$0.1B–28
2019––$-0.0B$0.1B–38
2020––$-0.1B$0.1B–29
2021––$-0.1B$0.2B–23
2022––$-0.1B$0.2B–13
2023––$-0.1B$0.6B–6
2024$0.1B$-0.1B$-0.1B$0.5B-259.610
2025$0.0B$-0.2B$-0.2B$0.4B–82

← See the full screener